What we are studying
The purpose of this study is to compare the drugs carboplatin and paclitaxel to a standard treatment for your type of cancer (paclitaxel plus ifosfamide and mesna). Based on results of other clinical trials, researchers think that the combination of carboplatin and paclitaxel may be as effective as the combination of ifosfamide and paclitaxel with fewer side effects. In this study you will get either the combination of paclitaxel and carboplatin or the combination of ifosfamide and mesna plus paclitaxel. You will not get both combinations. Mesna is a protective medication and not an anti-cancer chemotherapy.
Effectiveness of treatment will be measured in terms of survival, time without evidence of cancer growth, shrinkage of the tumor for those patients who have tumors that can be visualized by scans, and quality of life (wellness and physical functioning).